Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 4, 2014, Pages 491-498

  Katz, Lior H ^a   Kopylov, Uri ^a   Fudim, Ella ^a   Yavzori, Miri ^a   Picard, Orit ^a   Ungar, Bella ^a   Eliakim, Rami ^a   Ben Horin, Shomron ^a   Chowers, Yehuda ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 2; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CROHN DISEASE; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INFLAMMATORY BOWEL DISEASE; INTESTINE BIOPSY; LAMINA PROPRIA; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS; BIOSYNTHESIS; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKIN-2; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84912525905     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.01.010     Document Type: Article

References (41)

1. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007, 117:514-521.
2. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 2002, 347:417-429.
3. Hundorfean G., Neurath M.F., Mudter J. Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:180-186.
4. Heller F., Florian P., Bojarski C., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005, 129:550-564.
5. Fujino S., Andoh A., Bamba S., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52:65-70.
6. Seiderer J., Elben I., Diegelmann J., et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008, 14:437-445.
7. Veny M., Esteller M., Ricart E., Pique J.M., Panes J., Salas A. Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients. Aliment Pharmacol Ther 2010, 31:561-572.
8. Hueber W., Sands B.E., Lewitzky S., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61(12):1693-1700.
9. Genovese M.C., Durez P., Richards H.B., et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013, 72(6):863-869.
10. Rich P., Sigurgeirsson B., Thaci D.P., et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013, 168(2):402-411.
11. Marquez A., Orozco G., Martinez A., et al. Novel association of the interleukin 2-interleukin 21 region with inflammatory bowel disease. Am J Gastroenterol 2009, 104:1968-1975.
12. Reinisch W., Sandborn W.J., Rutgeerts P., et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012, 18:201-211.
13. Sandborn W.J., Hanauer S.B. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002, 97:2962-2972.
14. Sandborn W.J., Rutgeerts P., Feagan B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260. [quiz 520].
15. Peternel S., Prpic-Massari L., Guina T., Novak S., Brajac I., Kastelan M. Treatment of severe psoriasis with infliximab: report of two cases. Acta Dermatovenerol Croat 2009, 17:204-206.
16. Tam L.S., Shang Q., Li E.K., et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis-a randomized trial. J Rheumatol 2012, 39(12):2267-2275.
17. Holtta V., Sipponen T., Westerholm-Ormio M., et al. In Crohn's disease, anti-TNF-alpha treatment changes the balance between mucosal IL-17, FOXP3, and CD4 cells. ISRN Gastroenterol 2012, 2012:505432.
18. Nelson B.H. IL-2, regulatory T cells, and tolerance. J Immunol 2004, 172:3983-3988.
19. Kim E.Y., Teh H.S. Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J Immunol 2004, 173:4500-4509.
20. Kanayama K., Nakamura K., Ogino H., et al. Th1 responses are more susceptible to infliximab-mediated immunosuppression than Th17 responses. Dig Dis Sci 2011, 56:3525-3533.
21. Burchill M.A., Yang J., Vang K.B., Farrar M.A. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett 2007, 114:1-8.
22. Laurence A., Tato C.M., Davidson T.S., et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007, 26:371-381.
23. Maiti A.K., Kim-Howard X., Viswanathan P., et al. Confirmation of an association between rs6822844 at the Il2-Il21 region and multiple autoimmune diseases: evidence of a general susceptibility locus. Arthritis Rheum 2010, 62:323-329.
24. Hollis-Moffatt J.E., Gearry R.B., Barclay M.L., Merriman T.R., Roberts R.L. Consolidation of evidence for association of the KIAA1109-TENR-IL2-IL21 rs6822844 variant with Crohn's disease. Am J Gastroenterol 2010, 105:1204-1205. [author reply 6-7].
25. Glas J., Stallhofer J., Ripke S., et al. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am J Gastroenterol 2009, 104:1737-1744.
26. Festen E.A., Goyette P., Scott R., et al. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 2009, 58:799-804.
27. +) effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
28. Mangan P.R., Harrington L.E., O'Quinn D.B., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234.
29. Lee Y.K., Turner H., Maynard C.L., et al. Late Developmental Plasticity in the T Helper 17 Lineage. Immunity 2009, 30:92-107.
30. Ghoreschi K., Laurence A., Yang X.P., et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 2010, 467. 967-U144.
31. McGeachy M.J., Bak-Jensen K.S., Chen Y., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology. Nat Immunol 2007, 8:1390-1397.
32. Esplugues E., Huber S., Gagliani N., et al. Control of TH17 cells occurs in the small intestine. Nature 2011, 475:514-518.
33. Strober W., Fuss I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011, 140:1756-1767.
34. Ogawa A., Andoh A., Araki Y., Bamba T., Fujiyama Y. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 2004, 110:55-62.
35. Zenewicz L.A., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Stevens S., Flavell R.A. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008, 29:947-957.
36. Dige A., Stoy S., Rasmussen T.K., et al. Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease. J Crohns Colitis 2013, 7(3):248-255.
37. Kageyama Y., Takahashi M., Torikai E., et al. Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol 2007, 26:505-509.
38. Martinez-Borra J., Lopez-Larrea C., Gonzalez S., et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002, 97:2350-2356.
39. Maeda M., Watanabe N., Neda H., et al. Serum tumor necrosis factor activity in inflammatory bowel disease. Immunopharmacol Immunotoxicol 1992, 14:451-461.
40. Bouma G., Oudkerk Pool M., Scharenberg J.G., et al. Differences in the intrinsic capacity of peripheral blood mononuclear cells to produce tumor necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls. Scand J Gastroenterol 1995, 30:1095-1100.
41. Korczowska I., Lacki J.K., Hrycaj P. Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients. Yonsei Med J 2013, 54:183-188.